Baird Financial Group
MRVI icon

Baird Financial Group’s Maravai LifeSciences MRVI Stock Holding History

Baird Financial Group’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,349
Closed -$601K – 1889
2021
Q4 		$601K Sell
14,349
-20,376
-59% -$825K ﹤0.01% 1405
2021
Q3 		$1.7M Sell
34,725
-14,565
-30% -$710K ﹤0.01% 997
2021
Q2 		$2.06M Buy
49,290
+10,914
+28% +$423K 0.01% 911
2021
Q1 		$1.37M Buy
+38,376
New +$1.27M ﹤0.01% 1018

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baird Financial Group's MRVI Position: Q1 2022 in Review

Baird Financial Group sold out of Maravai LifeSciences (MRVI) in Q1 2022, closing a stake of 14,349 shares — an estimated $601K sold.

Baird Financial Group first reported a position in MRVI in Q1 2021 and held it in 4 quarters. The position peaked at $2.06M in Q2 2021. 235 funds tracked by Wall St. Rank hold MRVI as of Q1 2022.

  • Baird Financial Group reported no remaining Maravai LifeSciences position as of Q1 2022 after selling out during the quarter.
  • Baird Financial Group sold 14,349 Maravai LifeSciences shares in Q1 2022, an estimated $601K.
  • Baird Financial Group first reported a position in Maravai LifeSciences in Q1 2021 and held it in 4 quarters.
  • Baird Financial Group's Maravai LifeSciences position peaked at $2.06M in Q2 2021.
  • 235 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2022.

Based on Baird Financial Group's 13F filing for Q1 2022, filed 13 May 2022.